Clinical Trial Update: A Study Evaluating Gene Therapy With BB305 Lentiviral Vector in Sickle Cell Disease [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial evaluating BB305 Lentiviral Vector gene therapy for sickle cell disease is currently active but not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Sickle Cell Disease

Drugs mentioned

• BB305 Lentiviral Vector

Snippet

Sponsor: Genetix Biotherapeutics Inc. | Conditions: Sickle Cell Disease | Phase 3 | Status: ACTIVE_NOT_RECRUITING